JP6882339B2 - ペルアセチルガラクトースを使った組換えタンパク質のタンパク質ガラクトシル化プロファイルを改変する方法 - Google Patents
ペルアセチルガラクトースを使った組換えタンパク質のタンパク質ガラクトシル化プロファイルを改変する方法 Download PDFInfo
- Publication number
- JP6882339B2 JP6882339B2 JP2018559273A JP2018559273A JP6882339B2 JP 6882339 B2 JP6882339 B2 JP 6882339B2 JP 2018559273 A JP2018559273 A JP 2018559273A JP 2018559273 A JP2018559273 A JP 2018559273A JP 6882339 B2 JP6882339 B2 JP 6882339B2
- Authority
- JP
- Japan
- Prior art keywords
- cell
- peracetylgalactose
- protein
- culture
- medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title claims description 40
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title claims description 40
- 229930182830 galactose Natural products 0.000 title claims description 27
- 230000025098 protein galactosylation Effects 0.000 title description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 66
- 108090000623 proteins and genes Proteins 0.000 claims description 66
- 238000000034 method Methods 0.000 claims description 47
- 239000000427 antigen Substances 0.000 claims description 23
- 102000036639 antigens Human genes 0.000 claims description 23
- 108091007433 antigens Proteins 0.000 claims description 23
- 239000012634 fragment Substances 0.000 claims description 21
- 239000006143 cell culture medium Substances 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 230000009467 reduction Effects 0.000 claims description 11
- 230000012010 growth Effects 0.000 claims description 9
- 230000004048 modification Effects 0.000 claims description 9
- 238000012986 modification Methods 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 7
- 239000005556 hormone Substances 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 238000011081 inoculation Methods 0.000 claims description 3
- 210000001672 ovary Anatomy 0.000 claims description 3
- ZBQKPDHUDKSCRS-UHFFFAOYSA-N $l^{1}-oxidanyl acetate Chemical group CC(=O)O[O] ZBQKPDHUDKSCRS-UHFFFAOYSA-N 0.000 claims description 2
- 241000699802 Cricetulus griseus Species 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 238000010899 nucleation Methods 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 134
- 235000018102 proteins Nutrition 0.000 description 64
- 230000013595 glycosylation Effects 0.000 description 54
- 238000006206 glycosylation reaction Methods 0.000 description 51
- 239000002609 medium Substances 0.000 description 50
- 229960003082 galactose Drugs 0.000 description 48
- 230000000694 effects Effects 0.000 description 24
- 239000000203 mixture Substances 0.000 description 20
- 230000008859 change Effects 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 17
- 230000006870 function Effects 0.000 description 17
- 230000001225 therapeutic effect Effects 0.000 description 16
- 230000035899 viability Effects 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 15
- 238000004113 cell culture Methods 0.000 description 14
- 229920001542 oligosaccharide Polymers 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 230000009469 supplementation Effects 0.000 description 14
- 239000012526 feed medium Substances 0.000 description 13
- 239000013589 supplement Substances 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- 108060003951 Immunoglobulin Proteins 0.000 description 11
- 238000007792 addition Methods 0.000 description 11
- 230000004663 cell proliferation Effects 0.000 description 11
- 102000018358 immunoglobulin Human genes 0.000 description 11
- -1 peracetyl galactose Chemical compound 0.000 description 11
- 230000033581 fucosylation Effects 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 235000000346 sugar Nutrition 0.000 description 10
- 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 description 9
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 9
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 9
- 230000003833 cell viability Effects 0.000 description 9
- 150000004676 glycans Chemical class 0.000 description 9
- 238000009331 sowing Methods 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 210000004962 mammalian cell Anatomy 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 238000005621 mannosylation reaction Methods 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 150000002482 oligosaccharides Chemical class 0.000 description 6
- 230000010412 perfusion Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 5
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 5
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 5
- 241000508269 Psidium Species 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 4
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 4
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 4
- 230000002900 effect on cell Effects 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 150000002256 galaktoses Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 3
- 230000000153 supplemental effect Effects 0.000 description 3
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 102000002068 Glycopeptides Human genes 0.000 description 2
- 108010015899 Glycopeptides Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 2
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000012832 cell culture technique Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 102000054751 human RUNX1T1 Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000013028 medium composition Substances 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229960002450 ofatumumab Drugs 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 229960000160 recombinant therapeutic protein Drugs 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 1
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000106 biosimilars Drugs 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000001499 laser induced fluorescence spectroscopy Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940125645 monoclonal antibody drug Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 108010068617 neonatal Fc receptor Proteins 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000010925 quality by design Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229960003323 siltuximab Drugs 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16169062 | 2016-05-10 | ||
| EP16169062.3 | 2016-05-10 | ||
| PCT/EP2017/061181 WO2017194605A1 (en) | 2016-05-10 | 2017-05-10 | Methods for modulating protein galactosylation profiles of recombinant proteins using peracetyl galactose |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514411A JP2019514411A (ja) | 2019-06-06 |
| JP2019514411A5 JP2019514411A5 (enExample) | 2020-06-18 |
| JP6882339B2 true JP6882339B2 (ja) | 2021-06-02 |
Family
ID=56026651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559273A Active JP6882339B2 (ja) | 2016-05-10 | 2017-05-10 | ペルアセチルガラクトースを使った組換えタンパク質のタンパク質ガラクトシル化プロファイルを改変する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11118208B2 (enExample) |
| EP (1) | EP3455363B1 (enExample) |
| JP (1) | JP6882339B2 (enExample) |
| CN (1) | CN109072273B (enExample) |
| AU (2) | AU2017264541A1 (enExample) |
| CA (1) | CA3022769A1 (enExample) |
| ES (1) | ES2908067T3 (enExample) |
| IL (1) | IL262875B (enExample) |
| WO (1) | WO2017194605A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017117218A1 (en) | 2015-12-30 | 2017-07-06 | Momenta Pharmaceuticals, Inc. | Methods related to biologics |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| MX2021008030A (es) * | 2018-12-31 | 2021-08-05 | Momenta Pharmaceuticals Inc | Metodos para producir ustekinumab. |
| CN113549667A (zh) * | 2021-07-21 | 2021-10-26 | 杭州奕安济世生物药业有限公司 | 一种降低抗体半乳糖基化的方法 |
| WO2023161885A1 (en) * | 2022-02-25 | 2023-08-31 | Kashiv Biosciences, Llc | A process for improving polypeptide expression in mammalian cell culture |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102076865B (zh) * | 2008-05-02 | 2016-03-16 | 西雅图基因公司 | 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物 |
| WO2012019165A2 (en) * | 2010-08-05 | 2012-02-09 | Seattle Genetics, Inc. | Methods of inhibition of protein fucosylation in vivo using fucose analogs |
| CA2943667C (en) * | 2014-01-29 | 2022-11-08 | Lg Life Sciences Ltd. | Method for modulating galactosylation of recombinant protein through optimization of culture medium |
| WO2016022377A2 (en) * | 2014-08-05 | 2016-02-11 | Abbvie Inc. | Methods for modulating the glycosylation profile of recombinant proteins using dissolved oxygen |
-
2017
- 2017-05-10 CN CN201780028831.1A patent/CN109072273B/zh active Active
- 2017-05-10 ES ES17728776T patent/ES2908067T3/es active Active
- 2017-05-10 WO PCT/EP2017/061181 patent/WO2017194605A1/en not_active Ceased
- 2017-05-10 JP JP2018559273A patent/JP6882339B2/ja active Active
- 2017-05-10 AU AU2017264541A patent/AU2017264541A1/en not_active Abandoned
- 2017-05-10 US US16/300,066 patent/US11118208B2/en active Active
- 2017-05-10 EP EP17728776.0A patent/EP3455363B1/en active Active
- 2017-05-10 CA CA3022769A patent/CA3022769A1/en active Pending
-
2018
- 2018-11-08 IL IL262875A patent/IL262875B/en unknown
-
2021
- 2021-10-28 AU AU2021258023A patent/AU2021258023B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20190153497A1 (en) | 2019-05-23 |
| US11118208B2 (en) | 2021-09-14 |
| JP2019514411A (ja) | 2019-06-06 |
| IL262875B (en) | 2022-05-01 |
| CN109072273B (zh) | 2022-04-15 |
| EP3455363A1 (en) | 2019-03-20 |
| IL262875A (en) | 2018-12-31 |
| AU2021258023B2 (en) | 2023-11-16 |
| EP3455363B1 (en) | 2021-12-08 |
| CA3022769A1 (en) | 2017-11-16 |
| AU2021258023A1 (en) | 2021-11-25 |
| AU2017264541A1 (en) | 2018-12-13 |
| ES2908067T3 (es) | 2022-04-27 |
| WO2017194605A1 (en) | 2017-11-16 |
| CN109072273A (zh) | 2018-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7267284B2 (ja) | ポリエーテルイオノフォアを使用するタンパク質マンノシル化プロファイルの調節方法 | |
| JP6971221B2 (ja) | 組換えタンパク質のガラクトース含有量を増加させる方法 | |
| JP6882339B2 (ja) | ペルアセチルガラクトースを使った組換えタンパク質のタンパク質ガラクトシル化プロファイルを改変する方法 | |
| TWI832345B (zh) | 用於增加重組蛋白質之甘露糖含量之方法 | |
| CN113272440B (zh) | 改变细胞培养物中产生的重组糖蛋白的糖基化谱的方法 | |
| AU2016354052B2 (en) | Methods for modulating production profiles of recombinant proteins | |
| KR20230109674A (ko) | Fab 고 만노스 당형 | |
| KR102894782B1 (ko) | 세포 배양에서 생산된 재조합 당단백질의 글리코실화 프로파일의 변형 방법 | |
| JP2019526265A (ja) | 組換えタンパク質の生産プロファイルを改変するための方法 | |
| CN115537445A (zh) | 用含尿苷和n-乙酰葡糖胺的培养基调节甘露聚糖糖型 | |
| HK40089653A (zh) | Fab高甘露糖糖型 | |
| WO2016162514A1 (en) | Methods for modulating protein glycosylation profiles of recombinant proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200501 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200501 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201125 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201208 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210305 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210406 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210506 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6882339 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |